Nicox

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Nicox glaucoma drug works, but not as well as hoped

Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks